Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00924053 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes
A Phase 1 study, sponsored by Theracos.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00924053 is a Phase 1 study that has completed, run by Theracos. The registered enrollment target is 24 participants.
The verdict
NCT00924053, a Phase 1 study, has completed, sponsored by Theracos.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics (how much of the drug gets into the blood and how long it takes the body to get rid of it) of single doses of EGT0001474 given to patients with Type 2 diabetes. The study will also evaluate how EGT0001474 affects the amount of glucose produced by the body in the urine.
Interventions
- DRUG Placebo
- DRUG EGT0001474
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00924053
The ClinicalTrials.gov registry entry for NCT00924053 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theracos, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00924053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00924053 about?
NCT00924053 is a clinical study titled "Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes". The purpose of this study is to determine the safety, tolerability and pharmacokinetics (how much of the drug gets into the blood and how long it takes the body to get rid of it) of single doses of EGT0001474 given to patients with Type 2 diabetes. The study will also evaluate how EGT0001474 affects...
What is the current status of trial NCT00924053?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-06. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00924053?
The interventions under investigation include: Placebo (DRUG), EGT0001474 (DRUG).
Who is sponsoring clinical trial NCT00924053?
This trial is sponsored by Theracos, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.